BOCA RATON, FL--(Marketwire - Jan 29, 2013) - Modernizing Medicine, the creator of the Electronic Medical Assistant (EMA), a cloud-based specialty-specific EMR application, announced today that in 2012 the company launched into a new market and scaled massively in existing markets, winning the business of numerous physician practices. The company also entered into agreements with several key vendors, increased its staff to triple digits and secured its largest round of funding to date.

New Products and Gain in Market ShareIn October, Modernizing Medicine launched EMA Plastic Surgery at the American Society of Plastic Surgery's annual conference in New Orleans. The adoption rate of the already launched user-friendly and adaptive EMA Dermatology, EMA Ophthalmology and EMA Optometry grew by over 1000%, bringing the total number of providers using EMA to over 2,000.

Modernizing Medicine won the business of numerous large physician practices, including the Beatrice Keller Clinic, a full service dermatology clinic in Arizona with three offices and 17 physicians.States Dan A. Nelson MD, Medical Director, Beatrice Keller Clinic: "We researched a number of products and chose EMA due to the ease of use, speed and quality of the medical records produced.I would say that EMA is far more Derm specific with better Derm content, a workflow that fits Derm practice better and superior graphics and photo capabilities.EMAs competitors are less interesting for exactly the inverse reasons -- the workflow is designed for more general medicine with less specificity for Derm and inferior graphics and photo capabilities."

Strategic Agreements and EndorsementModernizing Medicine entered into agreements with several key vendors that have added tremendous value to EMA's users. Based on Modernizing Medicine's agreement with Logical Images, EMA Dermatology users now have the option to access Logical Images' VisualDx technology, which is a comprehensive digital image library with nearly 90,000 images representing all ages and skin types. Modernizing Medicine's agreement with Sonomed Escalon will provide EMA Ophthalmology users with the option to use AXIS image management software.

Modernizing Medicine also received an endorsement from the Inga Ellzey Practice Group, the leader in dermatology coding and billing.

Corporate Growth and Looking ForwardModernizing Medicine added 62 employees to its team in 2012, bringing the company total to 110 employees. Modernizing Medicine moved its headquarters from Boynton Beach, Florida to a larger office at the Research Park on the Florida Atlantic University campus in Boca Raton, Florida.

In 2012, Modernizing Medicine announced that it had closed a $12 million dollar capital raise, with a combination of equity capital and a senior debt bank facility, that was led by Pentland Group plc and joined by many of the company's own customers.

"What a year! I am thrilled with Modernizing Medicine's incredible growth in 2012 and could not be more proud of our amazing team," said Modernizing Medicine, co-Founder, President and CEO, Dan Cane. "From new product launches and key partnerships to unbelievable sales numbers and a strong funding round, we've done a lot this year.We are looking forward to a promising 2013 with the launch of EMA Cosmetic, EMA Orthopedics and EMA Otolaryngology."

About Modernizing Medicine Modernizing Medicine is delivering the next generation of electronic medical records (EMR) technology for the healthcare industry. Our product, Electronic Medical Assistant (EMA), is a cloud-based specialty-specific EMR with a massive library of built-in medical content, designed to save physicians time. Available as a native iPad application or from any web-enabled Mac or PC, EMA adapts to each provider's unique style of practice and is designed to interface with over 400 different practice management systems. Today, Modernizing Medicine provides specialty-specific offerings for the dermatology, ophthalmology, optometry and plastic surgery markets, and to more than 750 physician practices across the country.

Continued here:

Modernizing Medicine Sees Massive Adoption of Its EMR and More Than Doubles Staff in 2012

Wagon Wheel (Old Crow Medicine Show) - Joe Brady Cover
Wagon Wheel by Old Crow Medicine Show. Piano cover by Joe Brady.

By: JoeBrady48

Go here to read the rest:

Wagon Wheel (Old Crow Medicine Show) - Joe Brady Cover - Video

by Spokane Chiefs

KREM.com

Posted on January 27, 2013 at 12:24 AM

Medicine Hat scored the go-ahead goal at 7:54 in the third and held off a furious rally from Spokane as the Tigers defeated the Chiefs 4-3 in front of 7,910 fans at the Spokane Arena Saturday night. Todd Fiddler scored two goals and added one assist as the Chiefs fell to 16-9-0-0 at home and 30-18-2-0 overall.

The first period belonged to the net minders as the two teams combined for 30 shots but just one goal. Fiddler, who now leads the W.H.L. with 35 goals, provided that score at the 17:15 mark as he beat Cam Lanigan off a great feed from Mike Aviani.

Medicine Hat piled up 16 shots for the period but couldn't light the lamp as Garret Hughson excelled between the pipes in the early going.

The Tigers flipped the script in the second, scoring the period's only two goals despite being outshot 20-7 by the Chiefs. Boston Leier scored Medicine Hat's first goal at 3:49 and Hunter Shinkaruk gave the Tigers a 2-1 advantage as he snuck the puck past Hughson five-hole at the 8:30 mark.

The final stanza was a back-and-forth affair with the two teams trading goals at a breakneck pace to start the period. Spokane struck first just 8-seconds into the period as Todd Fiddler raced down the ice after the Chiefs won the faceoff and fired a shot past Lanigan glove-side for the score.

Fiddlers goal, assisted on by Brenden Kichton and Dylan Walchuk, tied the mark set by Tony Horacek in 1988 for the fastest goal to open a period in Chiefs history.

Medicine Hat responded with a score at 2:29 from Miles Koules only to see Blake Gal notch the equalizer 11-seconds later on assists from Fiddler and Walchuk. The Tigers Curtis Valk scored the game-winning goal on a power play at 7:54 and Lanigan kept Spokane off the board in a frenetic final minute of the game.

See original here:

Chiefs lose 4-3 to Medicine Hat

NEW ORLEANS, Jan. 28, 2013 /PRNewswire/ --Pamlab L.L.C., developer and marketer of Metanx, announced today that a multicenter study, done in collaboration with Tulane University, was published in The American Journal of Medicine. The study suggests that nutritional management of diabetic peripheral neuropathy (DPN) with L-methylfolate, methylcobalamin, and pyridoxal 5'-phosphate, a prescription medical food dispensed by prescription and commercially known as Metanx, improves total symptoms and health-related quality of life. The study, conducted by Vivian A. Fonseca, M.D. Tullis-Tulane Alumni Chair in Diabetes, Professor of Medicine and Chief, Section of Endocrinology at Tulane University School of Medicine, found significant improvement in both these areas after 24 weeks.

Type 2 Diabetes patients with symptomatic neuropathy often experience total symptoms including numbness, tingling and burning pain in the feet and/or hands. It is estimated that diabetic neuropathy affects 60-70 percent of the 26 million people in the U.S. with Type 2 diabetes. Nutritional management with Metanx is believed to regulate the metabolic processes responsible for maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves.

Two hundred fourteen patients with Type 2 DPN were enrolled in the multicenter, double blind, placebo-controlled study and were randomized 1:1 to receive either Metanx or identical placebo for 6 months. The Neuropathy Disability Score with Metanx demonstrated greater improvement than placebo at 16 weeks, as was the Neuropathy Total Symptom Score-6 (NTSS-6), which showed greater improvement at 16 and 24 weeks in the Metanx group than the placebo group. Significant improvement in quality of life was also observed with Metanx in the Short Form-36 (SF-36) Mental Component subscale after 24 weeks compared to placebo.

There were no differences in total adverse events in the Metanx group compared to the placebo group. Adverse events were infrequent, with each event that was reported occurring in <2% of all subjects.

Dr. Fonseca commented on the study, "This study demonstrated that significant improvements with Metanx were observed in measures of neuropathic symptoms and health-related quality of life, factors which may have a greater impact on patients' well being. This verifies that Metanx could be a useful tool in managing patients with symptomatic diabetic neuropathy. Unlike current therapies on the market, Metanx has a unique mechanism of action that may be related to the pathophysiology of Diabetic Peripheral Neuropathy. I am delighted that Tulane University was able to work with Metanx (Pamlab, L.L.C.), a New Orleans area health care company, to conduct research that improves the lives of patients with diabetes."

The study can be found in The American Journal of Medicine and online here: http://www.ncbi.nlm.nih.gov/pubmed/23218892

About Diabetic NeuropathyDiabetic neuropathy, or nerve damage caused by diabetes, is a chronic, progressive condition characterized by tingling, burning pain and numbness in the feet and/or hands. Numbness in the feet is the most common symptom associated with diabetic neuropathy and is the most frequent cause of ulceration and non-traumatic amputation. Additionally, burning pain occurs in 10 to 25 percent of DPN patients. Current therapies mask the painful symptoms of DPN but do not address the natural history of the disease, a challenge currently facing healthcare providers.

About Medical Foods and MetanxMedical foods are specially formulated to manage a specific disease or condition for which medical evaluation, based on recognized scientific principles, has established distinct nutritional requirements. All components of a medical food must have GRAS status (Generally Recognized as Safe) or be an approved food additive.

Metanx is a medical food dispensed by prescription and indicated for the distinct nutritional requirements of patients with endothelial dysfunction who present with loss of protective sensation and neuropathic pain associated with diabetic neuropathy. Metanx offers a nutritional benefit by improving endothelial function and maintaining blood flow in the vessels that carry important nutrients and oxygen to the peripheral nerves.

About Pamlab, L.L.C.Pamlab, L.L.C., founded in 1957, is a fully integrated pharmaceutical company specializing in medical foods indicated for the nutritional support of specific disease states including diabetic neuropathy, depression and mild cognitive impairment.

See the rest here:

Tulane University Study Published In The American Journal of Medicine Finds Nutritional Management With Metanx® ...

When you were 15, chances are, revolutionizing medicine wasn't among your after-school activities. But for 15-year-old Jack Andraka, it's par for the course. The high school sophomore recently developed a revolutionary new test for early-stage pancreatic cancer. This, before he could legally drive a car.

This past December, Andraka won Intels prestigious Gordon E. Moore Award along with other top honors at the corporations annual Science and Engineering Fair, the worlds largest high school research and science competition. Jack Andraka created a simple dip-stick sensor to test for levels of mesothelin, which is a biomarker for early-stage pancreatic cancer thats found in blood and urine. The method is similar to diabetic testing strips, utilizing just a pinprick of blood and costing all of three cents to make.

Jack Andraka was moved by the frustrating realities of pancreatic cancer, a particularly lethal form of the disease, after a family friend passed away from it. But it wasn't until he was sitting in class sometime later that a solution struck him. Andraka tells TakePart, I came up with the idea when I was in science class. I was supposed to be paying attention, but then I had this epiphany.

Whats so revolutionary about Andraka's epiphany, aside from possibly being the most inexpensive medical test ever devised, is that current methods for pancreatic cancer detection are woefully ineffectivefor the most part, they're unable to uncover the presence of the disease until its in its final stages, long after it could respond to treatment. That's why the American Cancer Society reports that on average, the one-year survival rate for a patient is just 20 percent, and the five-year rate is a dismal four percent.

However, Andrakas prize-winning invention means patients could be armed with a simple method to detect the disease in its earliest incarnations, before it becomes invasive and when it still has a chance to respond to medical care. Early detection could bump up survival rates dramatically, edging them "close to 100 percent" according to Andraka. And for a disease that takes the lives of approximately 40,000 people each year, that's saying a lot.

But this is about more than pancreatic cancer. Andraka explains his strips can be altered to detect biomarkers for other conditions as well. Whats so cool about that is its applicability to other diseasesfor example other forms of cancer, tuberculosis, HIV, environmental contaminants like E Coli, salmonella, he says. All for three cents for a test that takes five minutes to run.

He has big plans to turn the medical community on its ear by mass marketing his work, making it widely available. He says, Essentially what Im envisioning here is that this could be on your shelf at your Walgreens, your Kmart. Lets say you suspect you have a conditionyou buy the test for that. And you can see immediately if you have it. Instead of your doctor being the doctor, youre the doctor. The teenager reports that hes already in talks with major corporations like LabCorp and QuestDiagnostics to bring his kits to store shelves as soon as possible, though how long that may actually take isnt yet known.

But if it seems like everything comes easily to the Maryland student, don't be fooled. While in the process of soliciting area labs for research space, he was rejected by 197 scientists, some of whom told him quite plainly his theory couldn't possibly work. Only one person said yes, but it turned out to be the right personDr. Anirban Maitra, a professor of pathology and oncology at Johns Hopkins University, who also became Jack's mentor.

It's easy to chalk up Jack Andraka's success to the luck that comes with being brillianthe is ridiculously smart. But there's more to him than that. His innate sense of social justice tells him that in a country as developed as ours, the fact that we have so many people dying every day of what could be a treatable disease is a wrong he intends to make right. "What motivates me is that 100 people die every day from pancreatic cancer. And so when I'm working I think those 100 people are who I'm working for today."

Is Jack Andraka an example of why we need more science in schools? Let us know what you think in the Comments.

Read more here:

Did This 15-Year-Old Kid Just Change the Course of Medicine?

PALO ALTO, Calif.--(BUSINESS WIRE)--

CardioDx, Inc. announced today that President and CEO, David Levison, and Chief Medical Officer, Mark Monane, M.D., will present at the 5th Annual Personalized Medicine World Conference (PMWC) on Tuesday, January 29, 2013 in Mountain View, CA. Mr. Levison will provide a company perspective on the reimbursement pathway for molecular diagnostic tests, and Dr. Monane will present an overview of Corus CAD, the only clinically validated gene expression test for obstructive coronary artery disease.

Corus CAD is a decision-making tool that can help primary care clinicians and cardiologists exclude obstructive coronary artery disease (CAD) as the cause of a stable non-diabetic patient's symptoms. The test involves a routine blood draw conveniently administered in the clinicians office, and does not expose patients to radiation or imaging agent intolerance. It is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has now been used to assess more than 35,000 U.S. patients.

We are living in one of the most exciting times in the evolution of medicine, and 2013 promises to be a pivotal year in the clinical adoption of personalized diagnostics and treatments, said Levison. By applying genomics to healthcare decision making, a healthcare practitioner can act on information that provides real-time insights on a patients disease state and prescribe the most suitable course of treatment for that patient. Unlike genetic tests which can only try to predict a persons predisposition to specific diseases, the Corus CAD gene expression test can help primary care clinicians and cardiologists exclude the diagnosis of obstructive CAD early in the diagnostic pathway, thus helping clinicians make better patient management decisions that may lead to improved quality of patient care, while lowering overall costs to the healthcare system.

Mr. Levison will present A Company Perspective on Reimbursement, discussing the opportunities and challenges in obtaining reimbursement coverage for molecular diagnostics and personalized medicine. Levison will share knowledge gained from the CardioDx experience in obtaining Medicare coverage for more than 40 million Medicare enrollees in the U.S. for the Corus CAD test. He will also review successful clinical strategies for working with payers to achieve positive coverage decisions and examine the role of Palmetto GBAs MolDx Program in clarifying the process and requirements for coverage. The presentation will take place on January 29 at 11:00 AM PT as part of Track 1, Session 4: Economics of PM.

Dr. Monane will provide an overview of CardioDx and Corus CAD, the only clinically validated cardiovascular genomic test designed to help clinicians safely, accurately, and conveniently determine from a blood sample whether their patients symptoms are due to blockages in the heart arteries. Corus CAD is a gene expression test that integrates the expression levels of 23 genes involved in the development of and/or response to atherosclerosis into a single score, which has been proven to accurately identify patients without obstructive CAD. Gene expression tests enable clinicians to act on genomic information and provide patients a more tailored management plan. The presentation is titled, Noninvasive Testing for Coronary Artery Disease and will take place on January 29 at 9:30 AM PT as part of Track 2, Session 7: Diagnostics and Healthcare Treatment.

About Corus CAD

Corus CAD is the first and only clinically validated blood-based test for the assessment of obstructive coronary artery disease. The test involves a routine blood draw conveniently administered in the clinicians office and does not expose patients to risks of radiation or imaging agent intolerance. It is the first sex-specific test for obstructive coronary artery disease, accounting for critical biological differences between men and women. The test has been honored as a winner of The Wall Street Journal's prestigious Technology Innovation Awards and one of TIME's Top Ten Medical Breakthroughs and is a finalist for the 2012 Edison Awards. Findings from the PREDICT validation study of the Corus CAD gene expression test were published in 2010 in the Annals of Internal Medicine, the journal of the American College of Physicians.

The Corus CAD test measures the RNA levels of 23 genes from a whole blood sample. Because these RNA levels are increased or decreased when obstructive coronary artery disease is present, the Corus CAD score indicates the likelihood that an individual patient does not have obstructive coronary artery disease.

Corus CAD is commercially available through an innovative patient sample kit that includes everything needed for blood collection and express delivery to the companys CLIA-certified Palo Alto, Calif. laboratory. Test results are delivered promptly to the clinicians office. Corus CAD is currently available in the United States.

More here:

CardioDx’s Leadership to Speak at the 5th Annual Personalized Medicine World Conference

(01-27-13) Al-Rastan | Homs | Childre Have No Medicine or Help, Mother Asks UN
http://www.facebook.com twitter.com Syrian victims are screaming for your help. Will you answer?

By: SyrianDaysOfRage

More here:

(01-27-13) Al-Rastan | Homs | Childre Have No Medicine or Help, Mother Asks UN - Video

My lovely medicine
"The Pretty Reckless-My Medicine (Single Version)" #9834; #9834; #9834; #1047; #1074; #1091; #1082; #1086; #1079; #1072; #1087; #1080; #1089; #1100; #1087; #1088; #1072; #1074; #1086; #1086; #1073; #1083; #1072; #1076; #1072; #1090; #1077; #1083; #1100;: UMG :::VKONTAKTE::: vk.com :::TWITTER::: twitter.com

By: #1040; #1088; #1090; #1077; #1084; #1057; #1086; #1083; #1086; #1074; #1100; #1077; #1074;

Continue reading here:

My lovely medicine - Video

Disco #39;s the Best Medicine
You #39;ll always feel better with a dose of Disco - no prescription needed, and no nasty lingering side effects. If you enjoyed this video, check out his others right here on YouTube; join Disco on Facebook and Twitter!

By: MsJumpinJude

Follow this link:

Disco's the Best Medicine - Video

Jeremy M. Berg, director of UPMCs new Institute for Personalized Medicine holds a model that he built of a protein that is mutated in human disease. Jasmine Goldband | Tribune-Review

Published: Saturday, January 26, 2013, 9:00p.m. Updated 14 hours ago

Drugs like Plavix, which prevents blood clots in people with coronary artery and vascular diseases, benefit millions of people.

But some people who take them find they dont work.

About 15 percent of people who take Plavix dont activate it properly. There are lots of people who are taking it who are not benefiting from it at all, said Jeremy Berg, a UPMC specialist in personalized medicine.

Personalized medicine tailors treatment to individuals based on increasingly accessible genetic information. The data are used, for example, to predict a patients likelihood of developing types of cancer, determine which therapies or drugs will work for diseases like asthma or even how to treat a particular case of influenza.

Berg, a bio-organic chemist with a doctorate in chemistry from Harvard University, is the first director of UPMCs new Institute for Personalized Medicine, announced this month.

The goal of setting up the institute, and others like it, is to make personalized medicine real. It improves the chances of getting better therapies and treatments to the public, Berg said.

Research being done into genetically informed treatments and therapies has been going on for years. UPMCs is the second personalized medicine institute to open in the state in the past 12 months, the other being the Hershey Institute for Personalized Medicine, operated by Penn State that opened in February.

Institutes such as these get treatments from research labs to patients, doctors and scientists said.

Here is the original post:

Institute for Personalized Medicine established by UPMC

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/7q6bf4/transfusion) has announced the addition of the "Transfusion Medicine Interactive: A Case Study Approach CD-ROM" report to their offering.

Transfusion Medicine Interactive, designed to complement the Practical Guide to Transfusion Medicine, is a CD-ROM that serves as an interactive textbook for those interested in understanding the practical aspects of clinical transfusion medicine. This is a handy reference that allows users to take advantage of the interactive benefits of receiving auditory and text feedback while managing complex, multi-part cases presented in a clinical-pathological conference format.

Transfusion Medicine Interactive demonstrates how to reach conclusions from current data and how to proceed in accumulating further data to ensure accurate diagnosis and management of blood banking and transfusion events.

Infinite Learning Potential

Topics of Interest

This CD-ROM ensures that there is something for everyone:

from medical technology students to physicians and nurses in training and in clinical practice. It is a great resource for medical professionals who are interested in advancing their clinical transfusion medicine training.

For more information visit http://www.researchandmarkets.com/research/7q6bf4/transfusion

See the original post here:

Research and Markets: Transfusion Medicine Interactive: A Case Study Approach CD-ROM Contains a Large Variety of Over ...

Cam Lanigan doesnt know if hes had 55 saves in a game before, but he knows hes never had two assists in a game. The Medicine Hat goaltender withstood Spokanes season-high 58 shots and set up two scores Saturday night to steer the Tigers toward a 4-3 win over the Chiefs at the Arena. The Tigers win, just their ninth on the road in 27 tries, denied the Chiefs their 1,000th win as a franchise. Medicine Hat (25-23-2-1), playing the Chiefs for the only time this season, recorded its eighth win in 11 games. Lanigan

You have viewed 20 free articles or blogs allowed within a 30-day period. FREE registration is now required for uninterrupted access.

S-R Media, The Spokesman-Review and Spokesman.com are happy to assist you. Contact Customer Service by email or call 800-338-8801

The Spokesman-Review photo

Spokane Chiefslogo (Full-size photo)

Cam Lanigan doesnt know if hes had 55 saves in a game before, but he knows hes never had two assists in a game.

The Medicine Hat goaltender withstood Spokanes season-high 58 shots and set up two scores Saturday night to steer the Tigers toward a 4-3 win over the Chiefs at the Arena.

The Tigers win, just their ninth on the road in 27 tries, denied the Chiefs their 1,000th win as a franchise. Medicine Hat (25-23-2-1), playing the Chiefs for the only time this season, recorded its eighth win in 11 games.

Lanigan assisted on the Tigers first score, Boston Leiers score at 3:39 of the second period to tie the game at 1. The goal occurred seconds after Spokanes Dylan Walchuk nearly scored.

Lanigan also notched an assist on the winner, Curtis Valks power-play goal with 12:06 left in the game after a Walchuk penalty.

Originally posted here:

Medicine Hat's Lanigan holds back Chiefs - Sat, 26 Jan 2013 PST

How to Integrate Green Medicine Into Pet Healthcare - Intro
This clip is a segment from the introduction to Dr. Jodie #39;s DVD - How To Integrate Green Medicine into Pet Healthcare

By: AnimalDoctorWI

Continue reading here:

How to Integrate Green Medicine Into Pet Healthcare - Intro - Video

Kolkata, Jan 24 (IANS) Predicting one's predisposition to addiction and warning potential victims to stay away from certain substances may become a reality in the near future, Indian scientists say.

New avenues in predictive medicine have also opened up with scientists at the Indian Institute of Chemical Biology identifying the presence of genetic mutations (or abnormal changes in the genes) responsible for addiction.

"This is a study in the area of predictive medicine. If we can identify the mutation in a gene which has association with addiction and if it's present in an individual, then we can predict that he or she is prone to addiction," Sumantra Das of the Neurobiology Division at the Indian Institute of Chemical Biology (IICB), told IANS.

IICB comes under the Council of Scientific and Industrial Research (CSIR).

Several mutations are known to exist in genes encoding certain proteins called opioid receptors through which narcotics like morphine and heroin exert their effects.

These receptors are of several classes. Two of them - mu opioid receptors (MOR) and kappa opioid receptors (KOR) - have been known to be associated with drug addiction.

While morphine, which acts through the mu opioid receptor, is widely used in controlling chronic pain, it leads to addiction in individuals in several cases.

The group of scientists had previously identified prevalence of a mutation in MOR in addicts in Kolkata. This mutation, A118G, is found in various populations all over the world.

In a recent study published in Progress in Neuro-Psychopharmacology & Biological Psychiatry Journal, the group has also identified a mutation in the KOR gene.

"KOR mutations are thought to be effective only when present with the MOR mutations," co-researcher Deepak Kumar explained.

View post:

Predictive medicine: Genes may identify potential addiction victims

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/5jb3zm/decision_making) has announced the addition of the "Decision Making in Transfusion Medicine" book to their offering.

This timely book examines the policy and clinical decisions being made today in the name of blood safety, often resulting in radical changes in transfusion medicine practice.

Although decision making in transfusion medicine is based on a wider range of inputs than solely the best research evidence, the orientation of this book remains evidence-based. In this capacity, the book is intended to serve one of the recurring principles enunciated by the FDA that decision making must be transparent. The book discusses both the evidence supporting and the hotly debated policy alternatives proposed for avoiding the risks of allogeneic blood transfusion.

Topics:

- The contrast between precautionary principle and evidence-based medicine.

- Emerging transmissible infections.

- Pathogen reduction.

- MSM donor deferrals.

- Patient blood management.

Continued here:

Research and Markets: The Book Decision Making in Transfusion Medicine Features Causes of, and strategies to reduce ...

By Chris Reidy, Globe Staff

Foundation Medicine Inc., a Cambridge biotechnology company using genomics data and DNA sequencing to help doctors pinpoint treatments for cancer patients, announced the appointment Wednesday of Steven J. Kafka to the newly created position of chief business officer.

Steven J. Kafka. Photo courtesy of Foundation Medicine.

Foundation Medicine is poised to expand the community of physicians, cancer centers, and pharmaceutical partners utilizing our services, Michael J. Pellini, M.D., the companys president and chief executive, said in a statement. Steve brings a valuable combination of strategic planning, financial, and operational expertise to help us drive capacity enhancements in our world-class CLIA-licensed laboratory, as well as a strong track record of building and leading successful pharmaceutical partnerships.

(CLIA stands for Clinical Laboratory Improvement Amendments in which Congress established quality standards for all laboratory testing to ensure the accuracy, reliability, and timeliness of patient test results.)

Kafka joins the company from Aileron Therapeutics, where he served as chief operating officer and chief financial officer, Foundation Medicine said in its press release.

Foundation Medicine was the subject of a recent Globe story, in part because Microsoft Corp. founder Bill Gates is an investor in the company.

Read the rest here:

Steven J. Kafka joins Foundation Medicine as chief business officer

OTT Breakfast Club Winter 2012: Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine
Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine Techid: 12022

By: EmoryUniversity

Original post:

OTT Breakfast Club Winter 2012: Human Stem Cells 3.0: The Holy Grail of Regenerative Medicine - Video

Public release date: 22-Jan-2013 [ | E-mail | Share ]

Contact: Marianne Morard morard@jeantet.ch 41-227-043-637 European Molecular Biology Organization

The 2013 LOUIS-JEANTET PRIZE FOR MEDICINE is awarded to the geneticist, Michael Stratton, director of the Wellcome Trust Sanger Institute in Cambridge, and jointly to the German biochemists Peter Hegemann, researcher at the Department of Experimental Biophysics at the Humboldt University, Berlin, and Georg Nagel, researcher at the Institute Julius-von-Sachs at the Biocenter, University of Wurzburg.

The LOUIS-JEANTET FOUNDATION grants the sum of CHF 700'000 for each of the two 2013 prizes, of which CHF 625'000 is for the continuation of the prize-winner's work and CHF 75'000 for their personal use.

THE PRIZE-WINNERS are conducting fundamental biological research which is expected to be of considerable significance for medicine.

MICHAEL STRATTON is awarded the 2013 Louis-Jeantet Prize for Medicine for his work aimed at understanding the genetic causes of human cancer.

The British researcher is one of the worldwide leaders in the study of cancer genomics and genetics. He notably directed the team that discovered the BRCA2 gene which, when mutated, causes predisposition to breast and ovarian cancer. Through the Cancer Genome Project started in 2000 at the Wellcome Trust Sanger Institute under his aegis, Michael Stratton demonstrated the presence of mutations in the BRAF gene in 60% of cases of malignant melanoma. Eight years later this discovery led to the development of new, and for the first time successful, treatments against this serious form of skin cancer.

Michael Stratton will use the prize money to conduct further research into cancer genetics at the early developmental stages.

PETER HEGEMANN and GEORG NAGEL are jointly awarded the 2013 Louis-Jeantet Prize for Medicine for their discovery of ion channels that can be activated by light. They have thus created a new and most promising discipline in the field of neurosciences - "optogenetics".

Peter Hegemann showed that photosensitive proteins controlled the movements of the microscopic green alga Chlamydomonas reinhardtii, which only moves in function of its exposure to light. Georg Nagel showed that rhodopsins from microbes, including the ones from the alga, can be brought into animal cells where they function well and their working can be studied. Together they studied the functionality of these proteins in depth. They thus discovered the unique property of ion channels that may be activated under exposure to light and are usable for the study of neural circuits in vitro and in vivo with so far unmatched levels of precision. The two researchers thus initiated a new discipline optogenetics - that offers an entirely new perspective for the treatment of certain neurological diseases in particular.

Follow this link:

2013 Louis-Jeantet Prize for Medicine

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/zdxf5h/radiology) has announced the addition of the "Radiology, Radiation Therapy and Nuclear Medicine, 3rd Edition 2013" report to their offering.

Clinical review criteria guidelines for radiology (including indications for MRI/CT), radiation therapy and nuclear medicine.

Health plan and Medicare benefit interpretations with useful references and related web links.

Some Key Topics Covered: Please click here for a full list

Radiology: Bone Mass Measurement/Bone mineral density (BMD) testing; Skeletal surveys in children; Scoliosis in children - indications for radiography; Cardiac scans for CAD; Cerebral angiography; Chest x-rays, routine; Cinedefecography; Contrast media; Spine - diagnostic radiology in adults and children; Imaging studies in acute low back pain; Myelography and Cisternography; Discography; Epidurogram/Epiduroscopy;

Breast imaging studies: Diaphanography of the breast; Mammography, screening or diagnostic/Digital/CAD mammography; Magnetic Resonance Imaging of the Breast: Differential Diagnosis; Breast Ultrasound and Echography; Stereotactic Breast Biopsy;

Diagnostic radiology: General; Extremity x-rays; Knee trauma;

MRI and CT scans: Computerized Tomography (CT) or Computerized Axial Tomography (CAT) - Overview; Computerized Tomography (CT or CAT) including extracranial head, brain and thoracic scans; High-resolution CT (HRCT) for Pulmonary Studies; CT for appendicitis; Spiral CT Scans for Lung Cancer Screening; Helical CT for Pulmonary Embolism Detection; Computerized Axial Tomography (CT) Scans: Pelvis, Abdomen, Abdomen and Pelvis - on the same day; Electron-beam CT screening for coronary artery disease; Ultrasound of peripheral sites (tibia, phalanges) for the selection of patients for pharmacologic treatment of osteoporosis;

Neuroimaging Studies for Headaches; Metastatic bone disease: Radiologic evaluation; Percutaneous Drainage/Aspiration of Abscesses and Fluid Collection; Percutaneous Permanent Inferior Vena Cava Placement; Percutaneous Transcatheter Embolization; Percutaneous Transluminal Angioplasty (PTA); Peripheral Vascular Disease Evaluation; Renal Artery Stenosis - Angiography and Stent Placement; Spiral CT for Lung Cancer Screening; Thermography;

See more here:

Research and Markets: Radiology, Radiation Therapy and Nuclear Medicine, 3rd Edition 2013

NEW YORK, January 23, 2013 /PRNewswire/ --

At the forefront of revolutionary medicine, Cannabis Science, Inc. (CBIS) [Full Research Report][1] has been heavily investing in the research and development of cannabis, otherwise known as marijuana. With focus on utilizing the medicinal use of marijuana, Cannabis Science is looking to bring medical treatments to areas such as cancer, PTSD and HIV. If the company achieves its goals, detractors may soon become supporters.

Debates on the use of marijuana have been growing despite its legalization in 18 states for medicinal purposes and 2 states for recreational use. While medical professionals continue to investigate and to further assess the benefits and risks of the drug, Cannabis Science is focused toward developing solutions within this new and ever expanding marketplace. Further driving the point home, Colorado recently granted recreational use of marijuana to its residents, a perfect fit for Cannabis Science's current base of operations.

Remaining Conservative

Being in Colorado is an advantage for Cannabis Science to let its business take-off. However, choosing to maintain a controlled position in terms of developing a still controversial drug is probably the company's smartest move. Although most Colorado residents would disagree, the executives of Cannabis Science may have already thought of the repercussions that may curb their business in the near future.

Finding cure for illnesses that are somewhat unheeded is the key to Cannabis Science's future success. If the company decides to follow its current trajectory, their stance towards medicinal revolution may attract more investors. It may seem to be a gamble for some investors, but for those who have bolder minds and wish to invest in high reward ventures, Cannabis Science is an investment that may be the key to unlock the future of biotechnology and medicine.

Reference Links:

[1] The Full Research Report on Cannabis Science, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.nationaltradersassociation.org/r/entire_report/6b90_CBIS]

Consider National Traders Association

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks.

Read more from the original source:

Cannabis Science May Unlock the Future of Biotech and Medicine